hydroxychloroquine has been researched along with HIV Coinfection in 34 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine has been used for treating malaria, rheumatoid arthritis, and lupus." | 2.68 | Treatment for HIV-related inflammation. ( , 1995) |
| "The rapid spread of the new Coronavirus Disease 2019 (COVID-19) has actually become the newest challenge for the healthcare system since, to date, there is not an effective treatment." | 2.66 | Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review. ( De Tommasi, N; Faraone, I; Labanca, F; Milella, L; Ponticelli, M, 2020) |
| "This review focuses on hepatic porphyrias, which include acute intermittent porphyria (AIP), variegate porphyria (VP), hereditary coproporphyria (HCP), aminolevulinic acid dehydratase deficiency porphyria (ADP), and porphyria cutanea tarda (PCT)." | 2.53 | Hepatic porphyria: A narrative review. ( Arora, S; Kodali, S; Singal, AK; Young, S, 2016) |
| " If the quinoline-based strategies should nevertheless be pursued in future studies, particular care must be devoted to the dosage selection, in order to maximize the chances to obtain effective in vivo drug concentrations." | 2.52 | Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS. ( Savarino, A; Shytaj, IL, 2015) |
| "However, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)/HIV-1 coinfection has been described in only few cases worldwide and no data are available on immunological outcomes in HIV-1-patients infected with SARS-CoV-2." | 1.56 | Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection: A case report. ( Antonelli, G; Bitossi, C; Borrazzo, C; Ceccarelli, G; d'Ettorre, G; Frasca, F; Innocenti, GP; Mastroianni, CM; Pinacchio, C; Recchia, G; Ridolfi, M; Santinelli, L; Scagnolari, C; Siccardi, G, 2020) |
| "Hydroxychloroquine has been proposed for HIV treatment; however, little is known about its disposition in the lymphatic system, where replication takes place." | 1.40 | Distribution of hydroxychloroquine in lymphoid tissue in a rabbit model for HIV infection. ( Aguirre-Cruz, L; González-Hernández, I; Jung-Cook, H; López-Arellano, R; Morales-Hipólito, A; Sotelo, J, 2014) |
| "Pulmonary hemorrhage is infrequently encountered in pediatrics." | 1.36 | Diffuse pulmonary hemorrhage as presenting syndrome of HIV disease. ( B Shah, V; Kumar, N; Prasad Goyal, J, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.88) | 18.2507 |
| 2000's | 5 (14.71) | 29.6817 |
| 2010's | 12 (35.29) | 24.3611 |
| 2020's | 15 (44.12) | 2.80 |
| Authors | Studies |
|---|---|
| Joharjy, H | 1 |
| Pisella, PJ | 1 |
| Audo, I | 1 |
| Le-Lez, ML | 1 |
| Polo, R | 1 |
| García-Albéniz, X | 1 |
| Terán, C | 1 |
| Morales, M | 1 |
| Rial-Crestelo, D | 1 |
| Garcinuño, MA | 1 |
| García Del Toro, M | 1 |
| Hita, C | 1 |
| Gómez-Sirvent, JL | 1 |
| Buzón, L | 1 |
| Díaz de Santiago, A | 1 |
| Arellano, JP | 1 |
| Sanz, J | 1 |
| Bachiller, P | 1 |
| Alfaro, EM | 1 |
| Díaz-Brito, V | 1 |
| Masiá, M | 1 |
| Hernández-Torres, A | 1 |
| Guerra, JM | 1 |
| Santos, J | 1 |
| Arazo, P | 1 |
| Muñoz, L | 1 |
| Arribas, JR | 1 |
| Martínez de Salazar, P | 1 |
| Moreno, S | 1 |
| Hernán, MA | 1 |
| Del Amo, J | 1 |
| Ridgway, JP | 1 |
| Farley, B | 1 |
| Benoit, JL | 1 |
| Frohne, C | 1 |
| Hazra, A | 1 |
| Pettit, N | 1 |
| Pho, M | 1 |
| Pursell, K | 1 |
| Saltzman, J | 1 |
| Schmitt, J | 1 |
| Uvin, AZ | 1 |
| Pitrak, D | 1 |
| McNulty, M | 1 |
| Modi, AR | 1 |
| Koval, CE | 1 |
| Taege, AJ | 1 |
| Modaresi Esfeh, J | 1 |
| Eghtesad, B | 1 |
| Narayanan Menon, KV | 1 |
| Quintini, C | 1 |
| Miller, C | 1 |
| Di Giambenedetto, S | 1 |
| Del Giacomo, P | 1 |
| Ciccullo, A | 1 |
| Porfidia, A | 1 |
| De Matteis, G | 1 |
| Cianci, R | 1 |
| De Vito, F | 1 |
| Dusina, A | 1 |
| Borghetti, A | 1 |
| Tumbarello, M | 1 |
| Kettelhut, A | 1 |
| Bowman, E | 1 |
| Funderburg, NT | 1 |
| Naghipour, S | 1 |
| Ghodousi, M | 1 |
| Rahsepar, S | 1 |
| Elyasi, S | 1 |
| Molina-Iturritza, E | 1 |
| San-José-Muñiz, I | 1 |
| Ganchegui-Aguirre, M | 1 |
| Balerdi-Sarasola, L | 1 |
| Ortiz-de-Zárate-Ibarra, Z | 1 |
| Gainzarain-Arana, JC | 1 |
| Portu-Zapirain, J | 1 |
| Di Biagio, A | 1 |
| Ricci, E | 1 |
| Calza, L | 1 |
| Squillace, N | 1 |
| Menzaghi, B | 1 |
| Rusconi, S | 1 |
| Orofino, G | 1 |
| Bargiacchi, O | 1 |
| Molteni, C | 1 |
| Valsecchi, L | 1 |
| Cenderello, G | 1 |
| Ferrara, S | 1 |
| Saracino, A | 1 |
| Maggi, P | 1 |
| Falasca, K | 1 |
| Taramasso, L | 1 |
| Bonfanti, P | 1 |
| Rivas, N | 1 |
| Espinoza, M | 1 |
| Loban, A | 1 |
| Luque, O | 1 |
| Jurado, J | 1 |
| Henry-Hurtado, N | 1 |
| Goodridge, A | 1 |
| d'Ettorre, G | 1 |
| Recchia, G | 1 |
| Ridolfi, M | 1 |
| Siccardi, G | 1 |
| Pinacchio, C | 1 |
| Innocenti, GP | 1 |
| Santinelli, L | 1 |
| Frasca, F | 1 |
| Bitossi, C | 1 |
| Ceccarelli, G | 1 |
| Borrazzo, C | 1 |
| Antonelli, G | 1 |
| Scagnolari, C | 1 |
| Mastroianni, CM | 1 |
| Kim, JY | 1 |
| Kim, JM | 1 |
| Peck, KR | 1 |
| Faraone, I | 1 |
| Labanca, F | 1 |
| Ponticelli, M | 1 |
| De Tommasi, N | 1 |
| Milella, L | 1 |
| Cui, X | 1 |
| Sun, J | 1 |
| Minkove, SJ | 1 |
| Li, Y | 1 |
| Cooper, D | 1 |
| Couse, Z | 1 |
| Eichacker, PQ | 1 |
| Torabi-Parizi, P | 1 |
| Traore, YL | 2 |
| Chen, Y | 3 |
| Padilla, F | 1 |
| Ho, EA | 3 |
| Lajoie, J | 2 |
| Mwangi, L | 2 |
| Fowke, KR | 2 |
| Birse, K | 1 |
| Cheruiyot, J | 1 |
| Akolo, M | 1 |
| Mungai, J | 1 |
| Boily-Larouche, G | 1 |
| Romas, L | 1 |
| Mutch, S | 1 |
| Kimani, M | 1 |
| Oyugi, J | 1 |
| Burgener, A | 1 |
| Kimani, J | 1 |
| González-Hernández, I | 1 |
| Aguirre-Cruz, L | 2 |
| Sotelo, J | 2 |
| López-Arellano, R | 1 |
| Morales-Hipólito, A | 1 |
| Jung-Cook, H | 2 |
| Savarino, A | 3 |
| Shytaj, IL | 1 |
| Bernier, AM | 1 |
| Arora, S | 1 |
| Young, S | 1 |
| Kodali, S | 1 |
| Singal, AK | 1 |
| Torres, KJ | 1 |
| Fortuny, C | 1 |
| Sánchez, E | 1 |
| Soda-Mehry, A | 1 |
| Reyes-Terán, G | 1 |
| Prasad Goyal, J | 1 |
| B Shah, V | 1 |
| Kumar, N | 1 |
| Piconi, S | 1 |
| Parisotto, S | 1 |
| Rizzardini, G | 1 |
| Passerini, S | 1 |
| Terzi, R | 1 |
| Argenteri, B | 1 |
| Meraviglia, P | 1 |
| Capetti, A | 1 |
| Biasin, M | 1 |
| Trabattoni, D | 1 |
| Clerici, M | 1 |
| Paton, NI | 3 |
| Goodall, RL | 1 |
| Dunn, DT | 1 |
| Franzen, S | 1 |
| Collaco-Moraes, Y | 1 |
| Gazzard, BG | 1 |
| Williams, IG | 1 |
| Fisher, MJ | 1 |
| Winston, A | 1 |
| Fox, J | 1 |
| Orkin, C | 1 |
| Herieka, EA | 1 |
| Ainsworth, JG | 1 |
| Post, FA | 1 |
| Wansbrough-Jones, M | 1 |
| Kelleher, P | 1 |
| Stein, JH | 1 |
| Hsue, PY | 1 |
| Massanella, M | 1 |
| Negredo, E | 1 |
| Puig, J | 1 |
| Puertas, MC | 1 |
| Buzón, MJ | 1 |
| Pérez-Álvarez, N | 1 |
| Carrillo, J | 1 |
| Clotet, B | 1 |
| Martínez-Picado, J | 1 |
| Blanco, J | 1 |
| Chamberlain, AJ | 1 |
| Hollowood, K | 1 |
| Turner, RJ | 1 |
| Byren, I | 1 |
| Aboulhab, J | 2 |
| Di Trani, L | 1 |
| Donatelli, I | 1 |
| Cauda, R | 1 |
| Cassone, A | 1 |
| Gennero, L | 1 |
| Sperber, K | 1 |
| Boelaert, JR | 1 |
| Karim, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Limiting HIV Target Cells by Inducing Immune Quiescence in the Female Genital Tract[NCT02079077] | 91 participants (Actual) | Interventional | 2014-04-30 | Completed | |||
| A Randomized Study to Compare the Efficacy of Vorinostat/Hydroxychloroquine/Maraviroc (VHM) in Controlling HIV After Treatment Interruption in Subjects Who Initiated ART During Acute HIV Infection[NCT02475915] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Pilot Study: Safety and Efficacy Study of Tripterygium Wilfordii Hook F Extract in cART-Treated HIV Patients With Poor Immune Responses[NCT02002286] | 23 participants (Actual) | Interventional | 2011-08-31 | Completed | |||
| Impact of Colchicine in Hospitalized Colombian Patients With COVID-19[NCT04539873] | Phase 3 | 128 participants (Actual) | Interventional | 2021-04-30 | Terminated (stopped due to non-inclusion of patients in the study effectively) | ||
| Prevention of COVID19 Infection by the Administration of Hydroxychloroquine to Institutionalized Older People and Nursing Home Staff. Controlled Clinical Trial, Randomized Triple Blind by Clusters (PREVICHARM Study)[NCT04400019] | Phase 2/Phase 3 | 1,930 participants (Anticipated) | Interventional | 2020-09-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
We will measure changes in the number of CD4+T cells expressing CCR5 at the female genital tract before and at the end of the study. (NCT02079077)
Timeframe: baseline and 8 weeks
| Intervention | percentage of cells (Median) |
|---|---|
| Acetylsalicylic Acid (ASA) | 17.60 |
| Hydroxychloroquine (HCQ) | 22.10 |
We will analyse reduce of immune activation by measuring change in T cell activation (CD69) between baseline and every month during drug administration phase (8 weeks). (NCT02079077)
Timeframe: Baseline and 8 weeks
| Intervention | percentage of cells (Mean) | |
|---|---|---|
| Average of CD4+CD69+ at baseline | Average of CD4+CD69+ T cells cells after treatment | |
| Acetylsalicylic Acid (ASA) | 4.04 | 4.9 |
| Hydroxychloroquine (HCQ) | 5.55 | 4.99 |
9 reviews available for hydroxychloroquine and HIV Coinfection
| Article | Year |
|---|---|
Coronavirus disease 2019 in an orthotopic liver transplant recipient living with human immunodeficiency virus.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; COVID-19; COVID-19 Drug Treatment; D | 2020 |
Immunomodulatory and Anti-Inflammatory Strategies to Reduce Comorbidity Risk in People with HIV.
Topics: Anti-Inflammatory Agents; Anti-Retroviral Agents; Antibodies, Monoclonal, Humanized; Comorbidity; Ga | 2020 |
Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.
Topics: Antimalarials; Antiviral Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Dru | 2020 |
Recent Clinical and Preclinical Studies of Hydroxychloroquine on RNA Viruses and Chronic Diseases: A Systematic Review.
Topics: Arthritis, Rheumatoid; Betacoronavirus; Chikungunya Fever; Chikungunya virus; Coronavirus Infections | 2020 |
Effects of chloroquine or hydroxychloroquine treatment on non-SARS-CoV2 viral infections: A systematic review of clinical studies.
Topics: Alphapapillomavirus; Antiviral Agents; Chikungunya Fever; Chikungunya virus; Chloroquine; COVID-19; | 2021 |
Preventing HIV infection without targeting the virus: how reducing HIV target cells at the genital tract is a new approach to HIV prevention.
Topics: Aspirin; Disease Susceptibility; Female; Genitalia, Female; HIV Infections; HIV Seronegativity; HIV- | 2017 |
Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS.
Topics: Antimalarials; Chloroquine; Drug Repositioning; HIV Infections; Humans; Hydroxychloroquine; Immunolo | 2015 |
Hepatic porphyria: A narrative review.
Topics: Acute Disease; Alcoholism; Biomarkers; Glucose; Hemin; Hemochromatosis; Hepatitis C; HIV Infections; | 2016 |
The anti-HIV-1 activity of chloroquine.
Topics: Anti-HIV Agents; Chloroquine; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Hydroxychlo | 2001 |
6 trials available for hydroxychloroquine and HIV Coinfection
| Article | Year |
|---|---|
Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers.
Topics: Adenine; Anti-HIV Agents; COVID-19; COVID-19 Drug Treatment; Deoxycytidine; Double-Blind Method; Emt | 2023 |
Using safe, affordable and accessible non-steroidal anti-inflammatory drugs to reduce the number of HIV target cells in the blood and at the female genital tract.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Genitalia, Female; HIV Infections; | 2018 |
Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Anti-Retroviral Agents; CD4 Lymphocyte Count; CD8-Posit | 2012 |
Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphoc | 2012 |
Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Viral; Drug Therapy, Comb | 2005 |
Treatment for HIV-related inflammation.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; CD4 Lymphocyte Count; Double-Blind Method | 1995 |
19 other studies available for hydroxychloroquine and HIV Coinfection
| Article | Year |
|---|---|
A Rare Case of Didanosine-Induced Mid-Peripheral Chorioretinal Atrophy Identified Incidentally 11 Years after the Drug Cessation.
Topics: Adult; Atrophy; Choroid Diseases; Didanosine; Emtricitabine; Female; HIV Infections; Humans; Hydroxy | 2022 |
A Case Series of Five People Living with HIV Hospitalized with COVID-19 in Chicago, Illinois.
Topics: Adult; Antiretroviral Therapy, Highly Active; Azithromycin; Betacoronavirus; CD4 Lymphocyte Count; C | 2020 |
SARS-CoV-2 infection in a highly experienced person living with HIV.
Topics: Aged; Anti-Bacterial Agents; Anti-HIV Agents; Antibodies, Monoclonal, Humanized; Betacoronavirus; Co | 2020 |
Coronavirus disease 2019 in patients with HIV in the province of Araba, Basque Country, Spain.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiviral Agents; Betacoronavirus; CD4 Lymphocyte Count; Coinfe | 2020 |
Factors associated with hospital admission for COVID-19 in HIV patients.
Topics: Antiviral Agents; Betacoronavirus; CD4 Lymphocyte Count; Coronavirus Infections; COVID-19; Female; H | 2020 |
Case Report: COVID-19 Recovery from Triple Infection with
Topics: Adult; Antitubercular Agents; Antiviral Agents; Betacoronavirus; Coinfection; Convalescence; Coronav | 2020 |
Analysis of type I IFN response and T cell activation in severe COVID-19/HIV-1 coinfection: A case report.
Topics: Anti-Retroviral Agents; Betacoronavirus; Case-Control Studies; CD4-Positive T-Lymphocytes; CD8-Posit | 2020 |
The First Case of an HIV Patient Diagnosed with COVID-19 in Korea.
Topics: Adult; Betacoronavirus; CD4 Lymphocyte Count; Coronavirus Infections; COVID-19; HIV Infections; Huma | 2020 |
Segmented intravaginal ring for the combination delivery of hydroxychloroquine and anti-CCR5 siRNA nanoparticles as a potential strategy for preventing HIV infection.
Topics: Administration, Intravaginal; Female; HIV Infections; Humans; Hydroxychloroquine; Nanoparticles; RNA | 2022 |
Distribution of hydroxychloroquine in lymphoid tissue in a rabbit model for HIV infection.
Topics: Animals; Anti-HIV Agents; HIV Infections; Hydroxychloroquine; Lymphoid Tissue; Male; Rabbits | 2014 |
Impact of Hydroxychloroquine-Loaded Polyurethane Intravaginal Rings on Lactobacilli.
Topics: Administration, Intravaginal; Cervix Uteri; Delayed-Action Preparations; Drug Delivery Systems; Elec | 2015 |
Short communication: preferential concentration of hydroxychloroquine in adenoid tissue of HIV-infected subjects.
Topics: Adenoids; Administration, Oral; Adult; Chemotherapy, Adjuvant; Chromatography, High Pressure Liquid; | 2010 |
Diffuse pulmonary hemorrhage as presenting syndrome of HIV disease.
Topics: Adrenal Cortex Hormones; AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Child, Prescho | 2010 |
Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders.
Topics: Anti-HIV Agents; Antigens, CD; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Posi | 2011 |
Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders.
Topics: Anti-HIV Agents; Antigens, CD; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Posi | 2011 |
Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders.
Topics: Anti-HIV Agents; Antigens, CD; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Posi | 2011 |
Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders.
Topics: Anti-HIV Agents; Antigens, CD; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Posi | 2011 |
Inflammation, immune activation, and CVD risk in individuals with HIV infection.
Topics: Anti-Inflammatory Agents; Aorta; Cardiovascular Diseases; Female; HIV Infections; Humans; Hydroxychl | 2012 |
Tumid lupus erythematosus occurring following highly active antiretroviral therapy for HIV infection: a manifestation of immune restoration.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dermatologic Agents; HIV Infecti | 2004 |
New insights into the antiviral effects of chloroquine.
Topics: Anti-HIV Agents; Antimalarials; Antiviral Agents; Chloroquine; Dose-Response Relationship, Drug; Dru | 2006 |
New insights into the antiviral effects of chloroquine.
Topics: Anti-HIV Agents; Antimalarials; Antiviral Agents; Chloroquine; Dose-Response Relationship, Drug; Dru | 2006 |
New insights into the antiviral effects of chloroquine.
Topics: Anti-HIV Agents; Antimalarials; Antiviral Agents; Chloroquine; Dose-Response Relationship, Drug; Dru | 2006 |
New insights into the antiviral effects of chloroquine.
Topics: Anti-HIV Agents; Antimalarials; Antiviral Agents; Chloroquine; Dose-Response Relationship, Drug; Dru | 2006 |
Hydroxychloroquine+ddI+Hydroxyurea antiretroviral trial, AIDS Research Alliance, Los Angeles.
Topics: Anti-HIV Agents; Antimalarials; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topi | 1999 |
Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Enzyme Inhibito | 2002 |